Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead Sciences 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 

2Q Revenues: $1.3 billion, (+22%)

2Q Earnings: $442.8 million (+9%)*

YTD Revenues: $2.5 billion (+22%)

YTD Earnings: $939.0 million (+15%)

Comments: Product sales were a record $1.2 billion in the quarter driven by the antiviral franchise ($1.1 billion, up 34%), including the strong growth of Atripla and continued growth of Truvada. Atripla sales were $355.1 million (+67%) and Truvada sales were $516.1 million (+34%). R&D expenses in the quarter were $176.5 million (+30%)

*Earnings in the quarter include an after-tax stock-based compensation expense of $26.4 million and an in-process research and development expense of $7.8 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters